Tumor progression despite massive influx of activated CD8+ T cells in a patient with malignant melanoma ascites

Keywords

Ascites, Melanoma, Cancer research, Medicine, CD8

References

• Progress in human tumour immunology and immunotherapySteven A. Rosenberg — 2001
• Roles of tumour localization, second signals and cross priming in cytotoxic T-cell inductionAdrian F. Ochsenbein, Sophie Sierro, Bernhard Odermatt — 2001
• Optimal T cell activation by melanoma cells depends on a minimal level of antigen transcription.Nathalie Labarrière, E Diez, Marie‐Christine Pandolfino — 1997
• Blocking Programmed Death-1 Ligand-PD-1 Interactions by Local Gene Therapy Results in Enhancement of Antitumor Effect of Secondary Lymphoid Tissue Chemokine1Yufei He, Guimei Zhang, Xiaohong Wang — 2004
• Indoleamine 2,3‐dioxygenase contributes to tumor cell evasion of T cell‐mediated rejectionMaria Friberg, Ronald Jennings, Marwan Alsarraj — 2002
• Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenaseCatherine Uyttenhove, Luc Pilotte, Ivan Théate — 2003
• Diversity and Recognition Efficiency of T Cell Responses to CancerTor B. Stuge, Susan Holmes, Sahdev Saharan — 2004
• Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanomaElke Jäger, Mark Ringhoffer, M. Altmannsberger — 1997
• Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytesSteven A. Rosenberg, Mark E. Dudley — 2004
• Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infectionsVictor Appay, P. Rod Dunbar, Margaret Callan — 2002
• Frequency and relative fraction of tumor antigen‐specific T cells among lymphocytes from melanoma‐invaded lymph nodesNathalie Labarrière, Marie‐Christine Pandolfino, Diane Raingeard — 1998
• Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance.Soldano Ferrone, Francesco M. Marincola — 1995
• Induction of peptide‐specific primary cytotoxic T lymphocyte responses from human peripheral bloodMagdalena Plebanski, Catherine E. M. Allsopp, Michael Aidoo — 1995
• Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockadeYoshiko Iwai, Masayoshi Ishida, Yoshimasa Tanaka — 2002
• Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance.Alfred Zippelius, Pascal Batard, Verena Rubio‐Godoy — 2004
• Tumors as elusive targets of T-cell-based active immunotherapy.Francesco M. Marincola, Ena Wang, Meenhard Herlyn — 2003
• Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.E.Y. Woo, Christina Chu, Theresa J. Goletz — 2001
• Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma.Amy Peterson, Helena Harlin, Thomas F. Gajewski — 2003
• Unique Chemotactic Response Profile and Specific Expression of Chemokine Receptors Ccr4 and Ccr8 by Cd4+Cd25+ Regulatory T CellsAndrea Iellem, Margherita Mariani, Rosmarie Lang — 2001
• PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T CellsChristian U. Blank, Ian E. Brown, Amy Peterson — 2004

Cited by

• Innate immune sensing of cancer: clues from an identified role for type I IFNsPaco Mota — 2012
• Inflammatory immune infiltration in human tumors: Role in pathogenesis and prognostic and diagnostic valueA. V. Bogolyubova, Pavel V. Belousov — 2016
• Dendritic-Cell (DC)-Based Immunotherapy: Tumor Endothelial Marker 8 (TEM8) Gene Expression of DC Vaccines Correlates with Clinical OutcomeElisabetta Bolli — 2008
• Beta-2-microglobulin gene transfer in hla class i deficient tumor cells using recombinant adenovirusC. Alonso, A. Del — 2014
• Immunological parameters as a new lead in the diagnosis of ovarian cancerThaïs Baert, D. Timmerman, I. Vergote — 2015
• The human T cell response to melanoma antigens.Pedro Romero, Jean‐Charles Cerottini, Daniel E. Speiser — 2006
• Persistence of Tumor-infiltrating CD8 T Cells is Tumor-dependent but Antigen-independentMobolaji O Olurinde, Ching-Hung Shen, Adam Drake — 2011
• Distinct Role for CD8 T Cells toward Cutaneous Tumors and Visceral Metastases1Renée Lengagne, Stéphanie Graff‐Dubois, Marylène Garcette — 2008
• Melanoma e inmunidadMaría Marcela Barrio — 2009
• The next hurdle in cancer immunotherapy: Overcoming the non-T cell-inflamed tumor microenvironmentThomas F. Gajewski — 2015
• PD‐1 expression on Melan‐A‐reactive T cells increases during progression to metastatic diseaseHolger Krönig, Kathrin Julia Falchner, Marcus Odendahl — 2012
• Tumor Response to Combination Celecoxib and Erlotinib Therapy in Non-small Cell Lung Cancer Is Associated with a Low Baseline Matrix Metalloproteinase-9 and a Decline in Serum-Soluble E-CadherinKaren L. Reckamp, Brian Gardner, Robert A. Figlin — 2008
• Phase- and stage-related proportions of T cells bearing the transcription factor FOXP3 infiltrate primary melanoma.Giuseppe De Panfilis, Nicoletta Campanini, Marcello Santini — 2008
• CD4+CD25+ regulatory T cells: a therapeutic target for liver diseasesMing‐Hua Zheng, Dian-na Gu, Martin Braddock — 2008
• Dendritic cell based antitumor vaccination: impact of functional indoleamine 2,3-dioxygenase expressionMarion Wobser, Heike Voigt, Roland Houben — 2007
• Early development of PAT-SM6 for the treatment of melanomaFrank Hensel, Miriam Eckstein, Andreas Rosenwald — 2013
• Selective accumulation of differentiated FOXP3+ CD4+ T cells in metastatic tumor lesions from melanoma patients compared to peripheral bloodCamilla Jandus, Gilles Bioley, Daniel E. Speiser — 2008
• Rapid Maturation of Effector T Cells in Tumors, but Not Lymphoid Organs, during Tumor RegressionLyse A. Norian, Paul M. Allen — 2007
• Molecular profiling of melanoma and the evolution of patient-specific therapyThomas F. Gajewski — 2011
• Antigen-specific versus Antigen-nonspecific Immunotherapeutic Approaches for Human Melanoma: The Need for Integration for Optimal Efficacy?Julia K. Tietze, Gail D. Sckisel, Hui-Hua Hsiao — 2011

Related papers

• The Relationship Between Serum CA125 Levels and Child-pugh Clas- sification of Liver Cirrhosis and Quantity of AscitesHong Du — 2006
• Analysis of clinical characteristic of the aged patients with ascitesWuliang Tang — 2009
• Natural history of grade 1 ascites in patients with liver cirrhosisTheodoros Theodorakopoulos — 2020
• Value of serum ascites albumin gradient in the etiological diagnosis of ascitesJun Hua — 2012
• Behavior and clinical impact of ascites after living donor liver transplantation: risk factors associated with massive ascitesDaisuke Ito, Nobuhisa Akamatsu, Junichi Togashi — 2016
• The Diagnostic Significance of Ascites Procalcitonin in Liver Cirrhosis with Spontaneous Bacterial PeritonitisWU Yun-hu — 2015
• miR-204-5p acts as a tumor suppressor by targeting matrix metalloproteinases-9 and B-cell lymphoma-2 in malignant melanomaWenkang Luan, Qian Yao, Xin Ni — 2017
• Regulation of melanoma malignancy by the RP11-705C15.3/miR-145-5p/NRAS/MAPK signaling axisXiangjun Chen, Sha Liu, Dongmei Han — 2020
• Allosteric and ATP-Competitive Inhibitors of mTOR Effectively Suppress Tumor Progression-Associated Epithelial-Mesenchymal Transition in the Kidneys of Tsc2+/− MiceAshley T. Jones, Jian Yang, Kalin Narov — 2019
• Overexpression of SLC25A51 promotes hepatocellular carcinoma progression by driving aerobic glycolysis through activation of SIRT5.Lu Bai, Zhao-Xu Yang, Pengfei Ma — 2022